A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Latest Information Update: 13 Jun 2025
At a glance
- Drugs VK 2019 (Primary)
- Indications Diffuse large B cell lymphoma; Epstein-Barr virus infections
- Focus Adverse reactions
Most Recent Events
- 06 Jun 2025 Status changed from not yet recruiting to recruiting.
- 01 May 2025 Planned initiation date changed from 31 Jan 2025 to 15 May 2025.
- 29 Jan 2025 New trial record